Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Individuel undersøgelse af genfodring for at optimere indlæggelsesgevinster (i-STRONG)

1. september 2026 opdateret af: University of California, San Francisco

Fornyelse af Multicenter Randomized Controlled Trial of Refeeding in Anorexia Nervosa

The primary purpose of the trial is to compare the efficacy and safety of Individualized Caloric Refeeding (ICR) to the new standard of care, Higher Calorie Refeeding (HCR), in hospitalized patients with atypical anorexia nervosa (AAN), and clinical remission over one year of follow-up.

Studieoversigt

Detaljeret beskrivelse

Atypical Anorexia Nervosa (AAN) is a new diagnosis describing patients with malnutrition and significant weight loss yet "normal" weight. These patients responded poorly to HCR, the superior refeeding treatment in the parent trial, which was designed for low-weight patients with typical AN. The proposed trial will examine the safety and efficacy of a new treatment for AAN with the potential to improve treatment outcomes for this diverse and growing patient population. The major finding motivating the proposed trial is that participants with AAN gained weight 40 percent slower and required 3.0 additional days in hospital to restore medical stability on HCR, as compared to AN. The research team has developed Individualized Caloric Refeeding (ICR), which doses calories to weight consistent with other pediatric treatments (e.g. medication).

The primary purpose of the proposed trial is to compare the efficacy and safety of ICR to the new standard of care (HCR) in hospitalized patients with AAN. The investigators hypothesize that ICR will restore medical stability faster than HCR with no increase in electrolyte abnormalities. After hospitalization, the major barrier to care in AAN is lack of consensus on clinical remission and whether these formerly overweight patients should gain weight to recover. The research team will examine metabolic, hormonal and psychological markers during long-term follow-up, toward the goal of developing a definition of clinical remission in AAN.

Design Summary: Randomized controlled trial in N=74 participants age 12-24 with AAN, consented upon hospital admission, randomly assigned to ICR or HCR, followed daily in hospital and at 3, 6, 9 and 12 mo.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

77

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford University Lucille Packard Children's Hospital
      • San Francisco, California, Forenede Stater, 94158
        • University of California, San Francisco Benioff Children's Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 24 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 12-24 yrs

  • Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for AAN

  • Hospitalized with medical instability, as defined by:

    1. night time heart rate (HR) <45 bpm,
    2. systolic blood pressure (SBP) <90 mmHg,
    3. temperature <35.6° C,
    4. orthostatic Δ HR >35 bpm, or
    5. orthostatic Δ SBP >20 mmHg

Exclusion Criteria:

  • Bulimia nervosa
  • Current pregnancy
  • Chronic disease (e.g. immune, renal disease)
  • Acute/active suicidality or psychosis
  • Hospital admissions for refeeding in the prior 6 mo.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Individualized Caloric Refeeding (ICR)

Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal

Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved

Andre navne:
  • ICR
Aktiv komparator: Higher Calorie Refeeding (HCR)

Starting 2000 kcal/d, increasing by 200 kcal/d to goal

Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved

Andre navne:
  • HCR

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to Achieve Medical Stability in Hospital
Tidsramme: Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks

Medical stability will be adjudicated by a five-point index: (1) 24 hour heart rate of 45 beats/min or more, (2) systolic blood pressure of 90 millimeters of mercury (mmHg) or more, (3) temperature of 35.6° C or more, (4) orthostatic increase in heart rate of 35 beats/min or less, (5) orthostatic change in systolic blood pressure of 20 mmHg or less.

Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Low Serum Electrolytes During Refeeding in Hospital
Tidsramme: Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks

Incidence of low electrolytes will be defined as: (1) hypophosphatemia less than 3 milligrams per deciliter (mg/dL), (2) hypomagnesaemia less than 1.8 mg/dL, and (3) hypokalemia less than 3.5 milliequivalent per liter (mEq/L) during hospitalization.

Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage Median BMI (mBMI) Over 12 Months
Tidsramme: 12 months post-study hospitalization

Measured BMI will be divided by the mBMI for age and sex per national growth data to give the percentage mBMI.

12 months post-study hospitalization
Eating Disorder Examination Questionnaire (EDE-Q) Score Over 12 Months
Tidsramme: 12 months post-study hospitalization

The EDE-Q will be self-administered; scores range from 0 to 6, with higher scores indicating greater severity and a worse outcome.

12 months post-study hospitalization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Andrea K Garber, PhD, RD, University of California, San Francisco
  • Ledende efterforsker: Neville H Golden, MD, Stanford University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. oktober 2021

Primær færdiggørelse (Faktiske)

3. juni 2025

Studieafslutning (Faktiske)

3. juni 2026

Datoer for studieregistrering

Først indsendt

8. juli 2021

Først indsendt, der opfyldte QC-kriterier

8. juli 2021

Først opslået (Faktiske)

19. juli 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2R01HD082166-06A1 (U.S. NIH-bevilling/kontrakt)
  • 20-32551 (Anden identifikator: UCSF IRB)
  • R01HD082166 (U.S. NIH-bevilling/kontrakt)
  • HD082166 (Anden identifikator: Federal Identifier, per NIH application)
  • P0547076 (Anden identifikator: NIH Application Identifier)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner